All In Biotech

Drug Trial Radar · NCT05118919

A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis

A Randomised Placebo-controlled Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Mild to Moderate Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Jun 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Feb 9, 2022

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
BioGaia Pharma ABIndustry
Sponsor type
Industry
First posted
Nov 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of Lactobacillus reuteri BGP-014 in mild to moderate active Ulcerative Colitis (UC) patients as an oral administered local treatment in addition to Standard of Care (SoC) treatment.

Conditions

  • Ulcerative Colitis

Interventions

  • BGP-014Biological

    Oral capsule containing lyophilised Lactobacillus reuteri

  • PlaceboBiological

    Oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and severity of adverse eventsTime frame: Up to 10 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Gastroenterology and Hepatology, Linköping University Hospital

    Linköping, Sweden

  • Gastroenterology Department, Danderyds Hospital

    Stockholm, Sweden

  • Gastroenterology Department, Ersta Hospital

    Stockholm, Sweden

  • Department of Medical Sciences Gastroenterology and Hepatology, Uppsala University Hospital

    Uppsala, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.